Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Dosage and administration of non-fucosylated anti-CD40 antibodies

Dosage and administration of non-fucosylated anti-CD40 antibodies

US Patent 11213584 · Granted Jan 4, 2022

Estimated economic value: $220,267,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Therapeutic vaccine for hepatitis b virus (HBV) using the HBV core antigen2025
Synergistic effects between auristatin-based antibody drug conjugates and inhibi2025
Methods of human retinal progenitor cell isolation and culture2025
Compositions and methods for treating retinal diseases2025
Methods of treating cancer with a combination of an anti-PD-1 antibody and an an2025
April and BAFF inhibitory immunomodulatory proteins and methods of use thereof2025
Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV PreS1 and/or PreS22025
APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof2025
CD47 antibodies and uses thereof for treating cancer2024
Anti-IL-6 antibody2024
CpG-oligodeoxynucleotide compounds in combination with immune modulators for can2024
T cells with reduced surface fucosylation and methods of making and using the sa2024